Lancet retracts letter on plight of nurses treating COVID-19 patients

The Lancet Global Health retracts a letter about the plight of nurses treating COVID-19 patients in Wuhan published on February 26. Can editors of peer-reviewed journals take a moral high-ground and make disparaging comments about preprints? On February 26, The Lancet Global Health retracted a letter by two nurses from Guangzhou province just two days … Continue reading Lancet retracts letter on plight of nurses treating COVID-19 patients

Advertisement

Waking up to MCPG toxin’s role in causing litchi mystery disease

There is evidence that as late as March 2014, Delhi’s National Centre for Disease Control, India (NCDC) and Centres for Disease Control and Prevention, Atlanta (CDC) researchers were in the dark about the possible role of methylenecyclopropylglycine (MCPG) toxin present in litchi in causing illness in children aged 15 years or younger in Muzaffarpur, Bihar … Continue reading Waking up to MCPG toxin’s role in causing litchi mystery disease

Lancet gets in touch with Current Science authors on litchi disease ethics issue

In response to an article I wrote on February 3 about Dr. Jacob John raising ethics issues about the way the authors of the Lancet Global Health paper had failed to properly acknowledge his team’s work on Muzaffarpur mystery disease, the journal has got in touch with Dr. Mukul Das, one of the authors of the Current Science … Continue reading Lancet gets in touch with Current Science authors on litchi disease ethics issue

Litchi: Controversy erupts over Muzaffarpur mystery disease study

The scientist who investigated the mystery disease that proved fatal for many 15-year old children in Muzaffarpur, Bihar at the instance of the State government has raised ethics issues about the way the research has been published by the journal Lancet Global Health on January 30. “Not giving due credit for work done by others … Continue reading Litchi: Controversy erupts over Muzaffarpur mystery disease study

India sets an example in subsidised TB diagnosis

There is a bright spot in an otherwise gloomy TB scenario in India. Of the 12 high-burden countries where the private sector is a major player in providing health care, the Indian private sector offers the cheapest price for the WHO-approved Xpert MTB/RIF, a molecular test for diagnosing TB. India also has the highest number … Continue reading India sets an example in subsidised TB diagnosis